Roche Asks Fed. Circ. To Revive Boniva Dosage Patents

Law360, Washington (December 6, 2013, 3:53 PM EST) -- Hoffmann-La Roche Inc. pushed a Federal Circuit panel on Friday to resurrect two of its patents covering the osteoporosis drug Boniva despite protests from several generic-drug makers, maintaining there was nothing in the record to support the lower court's obviousness finding.

Although the lower court determined that several prior art references and studies made Roche's once-monthly Boniva dosage obvious to those skilled the art, the company told the three-judge panel that there was no proof that the 150 milligram dose would be well tolerated by patients....
To view the full article, register now.